CBU
KRYS icon

CIBC Bancorp USA’s Krystal Biotech KRYS Stock Holding History

CIBC Bancorp USA’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$624K Buy
1,680
+415
+33% +$124K ﹤0.01% 1233
2026
Q1 		$327K Buy
+1,265
New +$337K ﹤0.01% 1379
2025
Q3 		$467K Buy
+2,643
New +$396K ﹤0.01% 900

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

CIBC Bancorp USA's KRYS Position: Q2 2026 in Review

CIBC Bancorp USA increased its Krystal Biotech (KRYS) stake by 33% in Q2 2026, buying an estimated $124K and bringing the position to 1,680 shares worth $624K. The position accounts for ﹤0.01% of the portfolio, ranked #1233.

CIBC Bancorp USA first reported a position in KRYS in Q3 2025 and has held it in 3 quarters since. 423 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • CIBC Bancorp USA held 1,680 shares of Krystal Biotech worth $624K as of Q2 2026.
  • CIBC Bancorp USA bought 415 Krystal Biotech shares in Q2 2026, an estimated $124K.
  • Krystal Biotech made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q2 2026, its #1233 holding.
  • CIBC Bancorp USA first reported a position in Krystal Biotech in Q3 2025 and has held it in 3 quarters since.
  • 423 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on CIBC Bancorp USA's 13F filing for Q2 2026, filed 13 Aug 2026.